A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 471-481

  Ilson, Bernard E ^a   Boike, Steven C ^a   Martin, David E ^a   Freed, Martin I ^a   Zariffa, Névine ^a   Jorkasky, Diane K ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; EPROSARTAN; PLACEBO;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACRYLATES; ADULT; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; MALE; POTASSIUM, DIETARY; RECEPTORS, ANGIOTENSIN; REFERENCE VALUES; RENAL CIRCULATION; SODIUM, DIETARY; THIOPHENES; TIME FACTORS;

EID: 0031900170     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90043-1     Document Type: Article

References (23)

1. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974;291:389-401.
2. Duncia JV, Chiu AT, Carini DJ, Gregory GB, Johnson AL, Price WA, et al. The discovery of potent non-peptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990;33:1312-29.
3. Weinstock J, Keenan RM, Samanen J, Hempel J, Finkelstein JA, Franz RG, et al. 1-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991;34:1514-7.
4. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260:175-81.
5. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR, Edwards RM, Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Arch Pharmacol 1992;345:673-8.
6. Hollenberg NK, Chenitz WR, Adams DF, Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal men. J Clin Invest 1974;54:34-42.
7. Hollenberg NK, Williams GH, Burger B, Ishikawa I, Adams DF. Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man. J Clin Invest 1976;57:39-46.
8. Earle DP, Berliner RW. A simplified clinical procedure for measurement of glomerular filtration rate and renal plasma flow. Proc Soc Exp Biol Med 1946;62:262-4.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Bratton AC, Marshall EK. A new coupling component for sulfanilamide determination. J Biol Chem 1939;128:537-50.
11. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996;28:961-6.
12. Brunner HR, Waeber B, Nussberger J. Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy? Hypertension 1983;5(suppl III):101-7.
13. Williams GH, Hollenberg NK, Brown C, Mersey JH. Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium restricted normal man. J Clin Endocrinol Metab 1978;47:725-31.
14. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI, et al. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res 1974; 40:69-77.
15. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1981;20:240-5.
16. Hollenberg NK, Swartz SL, Passan DR, Williams GH. Increased glomerular filtration rate following converting enzyme inhibition in essential hypertension. N Engl J Med 1979;301:9-12.
17. Williams GH, Hollenberg NK. Accentuated vascular and endocrine response to SQ 20881 in hypertension. N Engl J Med 1977;297:184-8.
18. Hollenberg NK, Fisher NDI. Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension 1995;26:602-9.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
20. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazapril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group [see comments]. N Engl J Med 1996;334:939-45.
21. Anderson S, Meyer TM, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76:612-9.
22. Zatz R, Dunn R, Meyer TM, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
23. Brenner BM. The experimental basis for designing strategies for arresting progression of renal disease. Presented at the American Society of Hypertension, New York, May 11-14, 1994.